« Back to Vicor Press Releases
Contact:
David H. Fater
President and Chief Executive Officer
(800) 998-9964
Hein J.J. Wellens, M.D. Joins Scientific Advisory Board
BOCA RATON, FLORIDA — November 9, 2004 — Vicor Technologies, Inc. ("Vicor" or "the Company") today announced that Hein J. J. Wellens, M.D. has joined Vicor's Scientific Advisory Board.
Hein J. J. Wellens, M.D. is a Professor and Chairman of the Department of Cardiology at Academisch Ziekenhuis Maastricht in Amsterdam, the Netherlands. He is a Director of the Interuniversity Cardiology Institute of the Netherlands and is a member of the Netherlands Academy of Arts and Sciences. He also has an appointment of visiting lecturer at Harvard Medical School. Between Dr. Wellens and Mark Josephson, M.D., another member of Vicor's Scientific Advisory Board, there have been more than 1,000 articles and nearly two dozen books published covering all aspects of arrhythmology and electrophysiology. The vast experience of both Drs. Wellens and Josephson includes all areas of diagnostic and therapeutic aspects of the entire spectrum of clinically occurring arrhythmias. They are internationally recognized leaders in the field.
Commenting on the relationship, David H. Fater, President and Chief Executive Officer of Vicor said, "We are extremely pleased and delighted to have a renowned European electrophysiologist with Dr. Wellens's background and credentials join our Scientific Advisory Board. His clinical knowledge and perspective will be vitally important as we commercialize the Vicor PD2i Cardiac Analyzer and expand into the European market. Between Dr. Josephson and Dr. Wellens, we are delighted as a company to have the support of these two thought leaders in the field."
Vicor Technologies, Inc. is a biotechnology company dedicated to the development of breakthrough diagnostic and therapeutic products. The Company's diagnostics products are based on the Company's patented PD2i algorithm, which is used to predict future pathological events, specifically but not limited to, fatal cardiac arrhythmic death, Alzheimer's Disease, and a number of other high profile diagnostic indications. Vicor's therapeutic products have been developed by using an innovative drug discovery platform which focuses on naturally occurring biomolecules derived from state-dependent physiologies such as hibernation.
Certain statements contained herein are "forward-looking" statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Vicor Technologies, Inc., prepared this update and is solely responsible for its content.